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Introduction. Glucocorticoids  (GKS) hormones with strong immunosuppressive  and anti-
inflammatory  activity  are  used,  inter  alia,  in  interstitial  lung diseases  (ILD).  GKS inhibit
excessive activity of inflammatory genes in the airways to induce apoptosis of immune cells,
such as alveolar lymphocytes (AL).
Objective. Assessment  of  cytoimmunological  changes  including  apoptosis  occurring  in
alveolar  lymphocytes  in  patients  with  selected  ILD  after  treatment  with  systemic
corticosteroids.
Methods. The  material  of  the  bronchoalveolar  lavage  (BAL)  derived  from patients  with
sarcoidosis (PS, n=66), idiopathic pulmonary fibrosis (IPF, n=27) and non-specific interstitial
pneumonia (NSIP, n = 25; adequate number of patients treated with systemic GKS were 23, 8
and 6) were analyzed in cytoimmunological tests: a) percentage and the total values of BAL
inflammatory cell populations; b) AL subset typing; c) CD4/CD8 index calculation; d) AL
cell cycle analysis (DNA staining with propidium iodide, PI); in techniques mentioned in b) to
d) items flow cytometry was used.
Results. In all  patient groups, treatment  with GKS resulted in a decrease in the total  cell
number, e.g. for PS (untreated: 310 ± 80x103/ml; treated: 188 ± 43x103/ml, median ± SEM,
p<0.05) and lymphocytes (untreated:  113 ± 71x103/ml;  treated:  43 ± 25x103/ml median ±
SEM, p<0.05). There has also been significantly lower percentage of eosinophils in all groups
in GKS-treated subgroups, e.g. for IPF (untreated: 4,6 ± 3,0%, treated: 0,3 ± 0,5%), for NSIP
(untreated: 1,5 ± 0,7% and treated: with 0,4 ± 0,2%; median ± SEM, p<0.05 for both). In
contrast, AL apoptosis rate was significantly higher in treated patients, e.g. for PS (untreated:
0,6 ± 0,5%; treated: 4,0 ± 2,5%), NSIP (untreated: 3,4 ± 1,8%; treated: 13,1 ± 5,1%; median ±
SEM,  p<0.05  for  both).  In  all  GKS-treated  groups  corticosteroid  therapy  caused  lower
CD4/CD8 index, but only on the level of statistical tendency (e.g. for PS untreated: 4,7 ±
0,5%, treated: with 2,9 ± 0,9%) for IPF (untreated: 1,2 ± 0,5%, treated: with 1,1 ± 0,5%;
median ± SEM for both).
Conclusions. Systemic inflammatory glucocorticoid therapy (GKS) in all included groups of
patients results in a decrease in the total number of alveolar lymphocytes, which is most likely
related to the significant increase apoptosis rate of these cells. GKS medication in a similar
extent caused probably both the death of helper (Th) and cytotoxic lymphocytes (Tc), since
the decline in the value of CD4/CD8 index in treated patients compared with untreated ones
was  insignificant.  A  characteristic  BAL cytological  change  in  all  tested  ILD  after  GKS
administration was a remarkable decrease in eosinophil percentage.
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Introduction
Interstitial lung diseases (ILD) is a heterogeneous group of diseases in which the main
pathological phenomenon is chronic inflammation of the bronchioles and alveoli caused by
exposure to a given factor.  With the progression of the disease,  this  process involves the
pulmonary vessels, the lower respiratory tract, which can lead to pulmonary fibrosis [1,2].
The examination, which has a significant importance in the diagnosis of interstitial diseases, is
bronchoalveolar  lavage  (BAL)  [3,4]. For  the  purpose  of  this  study,  using  BAL material,
attempts  were  made  to  assess  alterations  in  the  cytoimmunological image,  specifically
changes  in  immune  system  function  and  cells’  phenotype  after  the  treatment  with
glucocorticoid therapy (GKS) at patients with selected interstitial lung diseases: sarcoidosis
(PS), idiopathic pulmonary fibrosis (IPF) , nonspecific interstitial pneumonia (NSIP).
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Sarcoidosis is a disease characterized by unknown etiology, the onset of the disease is
chronic or subacute, fibrosis is rare, and inflammatory cells are lymphocytes and monocytes.
In this disease, the population of CD4 + cells predominates. In IPF, the etiology is also not
known, the beginning is of the type as in the case of sarcoidosis (the onset is chronic, when in
PS - it is sometimes severe, as the so-called Loefgren syndrome). In addition, it differs from
the  previous  disease  entity,  the  presumed predominance  of  CD8 + lymphocytes,  and the
inflammatory  cells  are  mainly  eosinophils  and  neutrophils.  Fibers  are  always  present.
However, fibrosis is common in NSIP, although in the form of so-called cell phones it appears
late [5]. The treatment used in interstitial lung diseases is, among others corticotherapy.
Glucocorticoids are hormones that are important regulators of the body's homeostasis
[6,7,8,9]. Due to their multi-faceted effect, they have found application in the treatment of
inflammatory diseases, among others in interstitial lung diseases, acting in the genomic and
non-genomic  mechanism.  Steroids  penetrating  the  cell  connect  with  their  receptors  (GR,
glucocorticoid receptor), which causes the detachment of chaperone proteins, then the GKS-
GR complex travels to the cell nucleus where dimerization of the receptor takes place. This
results in the exposure of domains rich in zinc fingers, called DNA-binding domains. In this
manner, the GKS-GR complex is combined with the GRE (glucocorticoid response element)
within the promoters of the target genes. We differentiate GRE positive, which enhances gene
activation and GRE negative, which by combining with the target gene inhibit its expression
[10].
The most important effect of steroid therapy is the silencing of numerous pro-inflammatory
genes activated in the course of long-lasting inflammation [11]. According to the literature,
one of the most significant mechanisms of triggering T lymphocyte apoptosis by GKS is the
induction of Bim protein expression, along with the parallel inhibition of gene expression for
the Bcl-xL anti-apoptotic protein [12]. Another hypothesis suggests the effect of GKS on the
release of cathepsins by disintegrating lysosomes
Purpose of work
The aim of the study was to determine cytoimmunological changes, with particular emphasis
on the  process  of  apoptosis  in  follicular  lymphocytes  from the  lower  respiratory  tract  in
patients treated systemically with glucocorticosteroids in sarcoidosis, idiopathic pulmonary
fibrosis and nonspecific interstitial pneumonias.
Materials and methods
Examined groups
The  study  included  66  patients  with  sarcoidosis  (pulmonary  sarcoidosis,  PS,  including
untreated, n = 43 and treated, n = 23), 27 with idiopathic pulmonary fibrosis (IPF, including
untreated, n = 19 and treated, n = 8) and 25 with non-specific interstitial pneumonia (NSIP,
including untreated n = 19 and treated n = 6). BAL material  came from ill and untreated
patients whose the therapy lasted for 6 to 22 months. The research included the consent of the
Bioethical Commission of Collegium Medicum UMK (628/2014) with subsequent additions.
Bronchoalveolar lavage
BAL  (BALF,  bronchoalveolar  lavage  fluid)  was  performed  in  accordance  with  the
recommendations  of  the  European  Respiratory  Society  [13].  Briefly,  the  Olympus  Bf  20
bronchofiberoscope was used, patients were premedicated (Midazolam 2.5-5mg intravenous,
Atropina 0.5mg sub cutis);  the epiglottis  and trachea  were anaesthetized  with a local  2%
xylocaine solution. Bronchofiberoscopy was wedged in the bronchi of the medial lobe (right
lung). Buffered saline (37oC) was used in four equal portions of 50 ml, after each fraction the
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material was aspirated, filtered through sterile gauze, combined, mixed, collected in sterile
vessels and transported to the laboratory on ice [14].
Cytological and immunological tests of BAL material
The  principles  of  cytological  and  immunological  analysis  of  BAL  material  have  been
previously reported [14,15]. The viability of BAL cells was determined with trypan blue, their
total counts were calculated in a Bürker chamber; cytotoxic formulations (80g, 5min) were
stained with the May-Grünwald-Giemsa method (MGG) and hematoxylin-eosin (HE); in the
light  microscope,  the  percentage  formula  of  inflammation  cells  (inflow)  BAL  cells  was
calculated.  The  follicular  lymphocyte  (AL)  subpopulations  were  typed  by  direct
immunofluorescence technique. Briefly, the BAL material  was centrifuged and rinsed in a
PBS solution (300g, 8min), an amount of 1-5 x 105 BAL cells was incubated with saturating
amounts of mouse monoclonal antibodies (BD Pharmingen ™). A set of anti-CD45 FITC /
CD14 PE antibodies ("leucogate", used to define the field of lymphocytes in flow cytometry)
was  used  as  a  positive  control. To determine  the  expression  of  the  appropriate  cytokine
receptors  on Th (CD4) and Tc (CD8) cells,  a  set  of  antibodies  against  human HLA-DR,
TRAIL,  CD27,  CD25,  CD16  +  56,  CD19,  CD3,  CD4  and  CD8  antigens  were  used,
conjugated with fluorescent dyes FITC, PE and PE-Cy5. Cells  expressing the test  antigen
emitted light in the standard FL1 fluorescence channels (green light), FL2 (bright red) and
FL3 (dark red), respectively. As a negative control, isotype-compatible mouse antibodies with
working antibodies  used in  the  work  were  used.  Details,  including  the  type  of  antibody-
conjugated fluorochromes, are given in Table 1. Incubation of BAL cells with antibodies (30
min. No light) was discontinued with PBS solution with 0.1% sodium azide, cells were rinsed
and suspended in 0.3ml PBS with 1 % formaldehyde additive [16]
The BD FACSCalibur flow cytometer (488nm argon laser) collected data for at least 10,000
cells of each individual sample, including their sizes (forward scatter, FSC), side scatter, SSC
and fluorescence intensity FL1, FL2 and FL3 . The results were calculated as a percentage of
positive  BAL lymphocytes  in  a  given  stain.  Defining  the  AL field.  in  the  CD45 /  SSC
parameter system, detailed criteria for the qualification of BAL material for testing and the
conditions of cytometric analysis were previously described [16].
337
Table 1. Monoclonal antibodies used in flow cytometry analysis.




Leucogate (CD45/CD14) FITC/PE 340040/BD Pharmingen
CD45 PerCy5 555490/BD Pharmingen
HLA-DR PE 347367/BD Pharmingen
CD4 FITC 345770/BD Pharmingen
CD8 PE 555367/BD Pharmingen
TRAIL PE 550516/BD Pharmingen
CD27 FITC 340424/BD Pharmingen
CD25 PE 555432/BD Pharmingen
Simultest CD3/CD16+CD56 FITC/PE 340300/BD Pharmingen
CD19 FITC 345776/BD Pharmingen
CD3 PerCP 345766/BD Pharmingen
FITC - fluorescein isothiocyanate,  PE - phycoerythrin,  PerCy5 - phycoerythrin-cyanine 5, PerCP - peridinin
chlorophyll protein
Cell cycle analysis in flow cytometry with staining of DNA with propidium iodide
The cell cycle was analyzed by flow cytometry with the staining of DNA with propidium
iodide (PI). In this study, the ability of PI to stochiometric DNA binding is used, making it
possible to assess cells in the late stage of apoptosis. In the histogram presentation of the
surface area of  pulses in the FL2 band (and therefore the specific for the excited PI light),
typical cell cycle phases are distinguished: G0 / G1 peak, S phase and G2 / M peak. In order
to fully penetrate the interior of the cell by PI, the cell suspension is incubated with surface-
active substances (e.g.,  Nonidet detergent).  Briefly, the BAL material was centrifuged and
rinsed first in a PBS solution (400g, 5min),  an amount of 1 x 10 6 BAL cells,  and then
incubated  and  under  the  same  conditions  2  times  centrifuged  in  NSS solution  (Nonidet,
propidium  iodide,  citrate  buffer).  250μl  of  RNase  solution  was  added  to  the  cells  and
incubated for 15 min, then 0.5ml of PBS was added and tested in a flow cytometer. Caluza
®Flow Analysis Software was used to analyze and visualize the results.
Statistical methods
Analysis of the data in statistical terms was performed using Statistica 10.0. The numbered,
non-parametricized  groups  studied  were  compared  using  the  Mann-Whitney  U  test.  The
obtained results were presented as median ± standard error of the mean (SEM), which were in
accordance  with  the  literature  [17].  Statistically  significant  differences  were  found  for  p
<0.05;  where  p  is  the  level  of  significance.  Differences  for  p  <0.1  were  also  taken  into
account as a trend.
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Results
Cytological results of BAL material
Figure 1 presents the percentage recovery of fluid BAL material from patients with
selected disease entities: PS, IPF, NSIP before and after glucocorticoid therapy (GKS). There
was  observed  a  statistically  significant,  with  a  significance  level  of  p  <0.05,  percentage
decrease in recovery after systemic treatment with GKS in the group of patients with IPF
(untreated: 50.5 ± 1.8%; treated: 45.0 ± 2.9%; median ± SEM). In the remaining groups, the
percentage of BAL fluid recovery after steroid treatment was reduced, however, it was not
statistically significant. 
Fig. 1. BAL fluid recovery %, the results are presented as median ± SEM values, p<0,05 
was considered significant.
Interestingly,  in  sarcoidosis  and  nonspecific  interstitial  pneumonia  a  statistically
significant decrease in the total number of cells was observed after treatment with GKS, PS
(untreated 310 ± 80x103 cells/ml, treated: 188 ± 43x103 cells/ml, median ± SEM), for NSIP
(untreated: 168 ± 62x103 cells/ml, treated: 160 ± 32x103 cells/ml, median ± SEM). However,
in the case of IPF we observe a slight increase (untreated: 140 ± 38x103 cells/ml, treated: 147
± 62x103 cells/ml, median ± SEM).
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Fig. 2. Total number of BAL cells,  the results are presented as median  ± SEM values,  
p<0,05 was considered significant.
Table 2 provides us with the cytological results of the BAL material considering the
selected cell populations in all the studied groups. In the BAL fluid of patients undergoing
corticotherapy  in  all  three  diseases,  a  statistically  significant  decrease  in  eosinophils  is
noticeable.  In  PS  (untreated:  1.1  ±  0.3%,  treated:  0.2  ±  0.3%,  median  ±  SEM),  in  IPF
(untreated: 4.6 ± 3.0%; treated: 0.3 ± 0.5%, median ± SEM), in NSIP (untreated: 1.5 ± 0.7%,
treated: 0.4 ± 0.2%, median ± SEM).



























































All  results  were  presented  as  median  ±  SEM. The  variable  value  range  (minimum-maximum) is  given  in
brackets, * p<0,05 was considered significant.
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In  BAL  fluid,  the  number  of  lymphocytes  in  all  examined  groups  descents  at  a
statistically significant level after the use of GKS preparations. For sarcoidosis (untreated: 112
± 71x103 cells/ml, median ± SEM; treated: 43 ± 25x103 cells/ml), for idiopathic pulmonary
fibrosis (untreated: 32 ± 7x103 cells/ml; treated: 18 ± 11x103 cells / ml; median ± SEM), for
non-specific  interstitial  pneumonia (untreated: 38 ± 30x103 cells  / ml,  treated:  20 ± 8x103
cells/ml, median ± SEM).
Fig. 3. Total number of alveolar lymphocytes, the results are presented as median ± SEM 
values, p<0,05 was considered significant.
Figure 3 displays the so-called the CD4/CD8 index, namely the ratio of CD4 + cells to
CD8 +. There was visible, at the level of statistical tendency (p <0.1), decrease in all groups
examined after treatment with glucocorticosteroids. For sarcoidosis (not treated: 4.7 ± 0.5%,
treated: 2.9 ± 0.9%, median ± SEM), for idiopathic pulmonary fibrosis (untreated: 1.2 ± 0.5%;
treated: 1, 02 ± 0.5%, median ± SEM), for non-specific interstitial pneumonia (untreated: 1.7
± 0.7%, treated: 1.2 ± 0.6%, median ± SEM).
Fig. 4. The CD4+/CD8+ ratio, the results are presented as median ± SEM values.
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In the study of BAL cell apoptosis in the sub-G1 phase of the cell cycle, attention is paid to
the higher percentage of apoptotic T lymphocytes in all examined groups after treatment with
glucocorticosteroids (p <0.05) for PS (untreated: 0.6 ± 0.5%; 4.0 ± 2.5%), IPF (untreated: 5.0
± 8.5%, median ± SEM, treated: 5.9 ± 1.3%), NSIP (untreated: 3.4 ± 1.8 %; treated: 13.1 ±
5.1%, median ± SEM, p <0.05.
Fig. 5. Alveolar lymphocytes (AL) apoptosis [%]; the results are presented as median ± SEM 
values, p<0,05 was considered significant.
Discussion
In studies carried out on experimental models, it was demonstrated that the Fas ligand
transcription factor, specifically the NF-κB complex, is inhibited by GKS preparations. The
beneficial  effect  of  corticosteroids  in  sarcoidosis  and  in  NSIP  probably  results  from the
inhibition of the NF-κB nuclear factor. In T lymphocytes, it becomes active due to ligation of
the TCR receptor with antigen. It works anti-apoptotic because it enhances the expression of
the  Bcl-2  and  Bcl-xL  genes.  Due  to  its  activity,  it  influences  the  intrinsic  pathway  of
apoptosis. The inhibition of its action by, for example, GKS preparations results in activation
of the above-mentioned Bim protein, expression of the gene that suppresses the p73 cell cycle
dependent on the p53 protein [18]. NF-κB is naturally blocked by an Iκβ inhibitor, whereas
phosphorylation of this inhibitor by IKK kinase leads to the activation of the NFκB factor,
which leads to the inhibition of a programmed cell death. In addition, the p22-FLIP factor
degradation product activates IKK kinase owing to which it can perform its function [19]. 
Literature  data  confirm that  glucocorticoids  activate  the  pro-apoptotic  Bim protein
[20].  This  polypeptide  is  important  from the  point  of  view of  the  NID mechanism.  The
combination of the TCR receptor with the antigen inhibits the Bim protein in the JNK / PKC
kinase signaling pathway. However, the Bim protein inhibits the antiapoptotic proteins of the
Bcl-2 family, which allows the opening of mitochondrial channels through other proapoptotic
factors Bak and Bax. Following, free radicals penetrate the mitochondria, damage the DNA,
and  activate  the  Puma-dependent  protein,  which  inevitably  tends  to  the  death  of  the
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lymphocyte  [21].  Considering  proteins  from  the  Bcl-2  family,  it  is  worth  mentioning
interleukin 7, which acts as a factor in the survival of follicular lymphocytes. Through JAK
kinases and STAT-5 family transcription factors, it activates the expression of Bcl-2 factor
[22]. Unfortunately, this cytokine promising to inhibit the inflammatory reaction seems to be
insensitive to the use of preparations from the GKS group [17].
A noteworthy protein is tumor necrosis factor  α (TNFα). T-lymphocytes expressing
the TNFR2 receptor use TNFα as a survival signal. The TNFR2 receptor at the death domain
has a structural TRAF motif that attaches the TRAF1 and 2 adapter proteins. The MAPK
kinase, JNK kinase pathway is activated and, most importantly,  the activation of the IKK
inhibitor  that  triggers  NFκB  factors,  the  role  of  which  has  been  described  above.  This
mechanism is worth noting due to the fact that in one of the studies, researchers showed that
in  people  suffering  from  sarcoidosis  after  using  corticotherapy  TNFα level  decreased
according  to  the  above-mentioned  mechanism  of  anti-inflammatory  action  of  GKS
preparations - by inhibition of proinflammatory cytokines as well as TNF [ 23].
GKS preparations also limit the expression of other inflammatory cytokines reactions,
such as IL-1, IL-2, INFγ. It is these cytokines that are secreted by Th1 lymphocytes and, as is
known, sarcoidosis is a disease in which the Th1 cell subpopulation predominates, while the
steroids  acting  on  the  GILZ  leucine  zipper  (glucocorticoid-induced  leucine  zipper)
additionally inhibit gene expression for T-bet (a factor protein transcriptional genes promoting
Th1 subpopulations [4] The above hypotheses quoted from the literature may be supported by
the  results  obtained in  the  present  study on the  increase  in  alveolar  cell  (AL)  apoptosis,
especially in sarcoidosis and NSIP, thus in diseases with a key role of Th1 cells. this was
statistically significant.
According to literature data, the problem of apoptotic effector T cells is not completely
clear. It is not certain whether the apoptosis of these cells is determined by the mechanism of
cell death induced by activation of AICD (activation of the induced cell death) or death by
NID (neglect induced death as a special example of cell death in the mitochondrial pathway).
The literature suggests that the interaction between Bim / Bcl-2 proteins may have a special
role  in  the  process  of  apoptosis.  Patients  with  significantly  low  apoptosis  of  follicular
lymphocytes  showed  high  expression  of  BCL-2  protein.  Conversely,  significantly  more
frequent apoptosis was observed in groups of patients with a decreased percentage of BCL-2
+ follicular lymphocytes [22]. Therefore, further research should focus on analyzing proteins,
transcription factors that bind to particular signaling pathways, in order to be able to assess
which one (extrinsic,  internal,  and possibly pseudoreceptor) is more often activated in the
context of the death of follicular lymphocytes.
The study shows that  after  the use of GKS preparations  in all  studied groups,  the
CD4 / CD8 index, that is the ratio of Th helper cells to Tc cytotoxic lymphocytes, decreased
in treated  patients  compared to untreated  patients.  These differences  were not  statistically
significant. It follows that CD4 + cells are more damaged by apoptosis induced by steroids.
For one group of patients this requires a comment. In the subgroup of sarcoidosis untreated
GKS, only cases of chronic sarcoidosis were considered, because in our opinion only such a
group can be compared with treated patients. The division proposed by Ziegenhegen [24] was
used,  according  to  which  three  forms  of  sarcoidosis  can  be  distinguished:  a)  Loefgren's
syndrome,  b)  chronic  progressive  disease  not  requiring  treatment,  c)  chronic  progressive
disease requiring treatment [24]. The individual cases of Loefgren's syndrome treated with
GKS have been omitted because the treatment of GKS is criticized in the literature as well as
due to the small number of cases. Therefore, the group of untreated patients included only
patients  with  chronic  sarcoidosis,  in  which  I,  II,  III  stage  of  radiological  progression  is
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distinguished [25]. Perhaps that is why the results from previous work [26], that is statistically
significant decrease in the CD4 / CD8 index in patients treated with sarcoidosis, were not
confirmed.  Well,  in  this  study,  this  observation  could  not  be  unambiguously  confirmed
despite the fact that the group treated with GKS preparations had a marked decrease in CD4 /
CD8 values, compared to untreated patients (more cases are necessary).
The  conducted  research  also  shows  that  the  percentage  and  activity  of  follicular
lymphocytes  decreases  in  all  three  diseases  in  patients  treated  with  glucocorticosteroids,
which would indicate a beneficial effect of GKS preparations, and this is in accordance with
the literature [27, 28]. An interesting fact from the point of view of this work are the results
indicating an insignificant increase in the percentage of neutrophils, which is in conflict with
literature  reports  that  signal  the  reduction  of  neutrophil  chemotaxis,  eg  by  inhibiting  the
expression  of  IL-8  [29].  Nevertheless,  this  issue  requires  further  research  on  a  more
representative group of patients.
For unknown reasons, lymphocytes at people suffering from IPF treated with GKS are
unlikely to be resistant - the conclusion is due to the lack of statistically significant differences
between the groups - despite the fact that the initial (in untreated patients) AL apoptosis is the
highest  of  all  three  analyzed units  disease.  This  corresponds to  the increasingly  common
belief that GKS preparations do not benefit in the treatment of IPF [23] but they cause many
side effects [30]. Despite this, doctors use GKS in default of other therapeutic options. In the
light of the results of this work, this is not a rational position, there are no interest changes (in
treated versus untreated) BAL neutrophils, currently considered important fibroblast inducing
cells. The case is still unclear and may be the subject of further research, however, because
another cell responsible for the deterioration of vital functions of IPF patients, probably the
progression of pulmonary fibrosis, eosinophilia, seems to be very sensitive, according to these
results, to the therapeutic effect of GKS. The results are confirmed in Meagher's work [31].
Finally, it should be noted that corticotherapy is not indicated if fibrosis has already occurred
[32]. This would amplify the view present in the literature data about their inhibitory effect,
first of all, differentiation into the Th1 subpopulation. The steroid preparations - as already
mentioned  -  activate  the  GILZ  protein  (glucocorticoid-induced  leucine  zipper)  which
suppresses the expression of the T-beta transcription factor involved in the maturation of Th1
lymphocytes. It is believed that the predominance of Th2 (and perhaps also Th17) over Th1 is
responsible for lung fibrosis and this is the case with IPF [33]. However, the current findings
regarding modifications in the T cell subpopulations, and in particular the Th1 / Th2 / Th17
polarization  disorder  are  not  definitive.  The next  step  that  could be done is  to  study the
markers of individual subpopulations of helper lymphocytes and to evaluate their expression.
Nonspecific interstitial pneumonitis is a disease of rather ambiguous pathogenesis. It is
postulated that this is a disorder characterized by a higher percentage of lymphocytes and
lower granulocytes compared to PS [34], and it is assumed, similarly to sarcoidosis (PS), that
shifting the immune response towards the Th1 subpopulation, and therefore Perhaps for this
reason, patients  respond well  to the use of corticotherapy [27,  28].  These arguments  also
support the results of the present study, because the apoptosis of follicular lymphocytes was
the  highest  of  all  the  groups  examined  after  treatment  with  GKS and it  was  statistically
significant  increase.  A  similar  result  is  seen  in  the  assessment  of  lymphocyte  activity
(decrease in the percentage of lymphocytes with the CD3 + HLA-DR + phenotype). The issue
of programmed death in BAL inflammatory cells has been very rarely studied [17]. Therefore,
it would be worth considering expanding research towards apoptosis and concentrating on
death receptors, their activity and role in pathogenesis.
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According  to  the  literature,  little  is  known  about  the  effect  of  neutrophils  on
lymphocyte apoptosis, and these cells are noteworthy because they are a source of oxygen
free  radicals  and  cathepsins,  and  recently  discovered  that  such  enzymes  are  involved  in
apoptosis of cells by inducing caspase-dependent death [35, 36], an interesting observation is
the fact that in this study after steroid therapy only sarcoidosis had a non-significant increase
in the percentage of neutrophils, and in the NSIP we noted a decrease, although the immune
response in both cases shifted towards the polarization of the cell phenotype Th1.
Earlier, it was reported that steroid-induced apoptosis was primarily damaged by CD3
+  lymphocytes  [37].  However,  in  the  light  of  this  work,  there  is  no  unambiguous  data
confirming this hypothesis. Submission of two observations: 1) decrease in the number and
percentage of lymphocytes in BAL material, 2) no statistically significant differences between
subgroups  of  treated  and  untreated  patients  in  the  subpopulation  of  lymphocytes  would
suggest that apoptosis under the influence of GKS preparations in more or less the same range
all three main BAL cell lymphocyte populations, namely T, B and NK cells [17].
In summary, in the light of the results we have received, we can come to three basic
conclusions.  In  all  diseases  studied:  sarcoidosis,  idiopathic  pulmonary  fibrosis  and  non-
specific interstitial pneumonia after the use of steroids, there is a significant decrease in the
number of follicular lymphocytes (AL) and an increase in apoptosis of these cells. Therefore,
the study of AL apoptosis can be used to assess the activity of the disease process, predict
remission of the disease, namely the absence of symptoms, and determine the sensitivity of
the inflammatory process to treatment with GKS. In addition, it is assumed that the main point
of regulation of apoptosis are CD4 + accessory lymphocytes, because the value of the CD4 /
CD8  index  was  reduced  in  all  groups  after  taking  steroid  preparations  (however
unprecedentedly,  which  we  emphasize  once  more,  but  was  explained,  too  little  of  the
examined cases).
IPF,  because  of  the  other  two  diseases,  postulated  by  the  literature  response  to
glucocorticoids is a disorder that should be paid more attention. In the light of this research,
the frequency of apoptosis increased after treatment with GKS. However, due to the conflict
between the reports and the research carried out for the purpose of this study, further research
into  the  determination  of  inflammatory  mediators  should  be  considered,  among  others
interleukin 2, interferon  γ, as well as BCL-2 protein, which overexpresses, as suggested by
Herold and co-authors, has a protective function against apoptosis induced by GKS. Studies
on transcription factors for individual lymphocyte subpopulations should not be omitted [17].
In  the  future,  new  therapeutic  approaches,  potentially  protecting  alveolar  cells  against
apoptosis, may be considered, as the use of glucocorticosteroids is unfavorable in diseases of
the occurring fibrosis,  the more so as it  has already been mentioned there probably is  an
unknown mechanism by which the Th2 subpopulation, which predominates in IPF escapes
from  the  programmed  death  of  a  cell  induced  by  steroids.  Perhaps  using  gene  therapy
techniques and making genetic modifications of transcription factors inducing or inhibiting
the programmed cell death process, we will be able to influence their expression in the course
of  interstitial  diseases  and presumably  change the  molecular  mechanism of  the  action  of
steroid drugs.
Conclusions
1. Systemic treatment with anti-inflammatory glucocorticosteroids in all the studied groups of
patients  results  in  a  significantly  lower  number  of  inflammatory  cells,  including
lymphocytes in the BAL material.
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2. The use of glucocorticosteroids  causes a decrease in the percentage of eosinophils  and
lymphocytes significantly for all groups of patients, and an increase in the percentage of
neutrophils for sarcoidosis.
3.  The probable  mechanism associated  with  a  decrease  in  the  number  and percentage  of
follicular lymphocytes after GKS administration is a significant increase in the frequency
of apoptosis, which was found in all examined groups. The frequency of BAL lymphocyte
apoptosis significantly correlates negatively with BAL lymphocytosis.
4. In all examined groups, GKS treatment reduced the CD4 / CD8 lymphocyte index value,
but that was not of significant nature. Presumably, GKS drugs in a similar range caused the
death of accessory lymphocytes as well as cytotoxic lymphocytes
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25. Kopiński  P.,  Balicka-Ślusarczyk  B.,  Dyczek  A.,  Szpechciński  A.,  Przybylski  G.,
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